Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aptevo Therapeutics (APVO) Short term Debt (2016 - 2022)

Aptevo Therapeutics' Short term Debt history spans 8 years, with the latest figure at $2.0 million for Q4 2022.

  • For Q4 2022, Short term Debt fell 82.86% year-over-year to $2.0 million; the TTM value through Dec 2022 reached $2.0 million, down 82.86%, while the annual FY2022 figure was $2.0 million, 82.86% down from the prior year.
  • Short term Debt for Q4 2022 was $2.0 million at Aptevo Therapeutics, roughly flat from $2.0 million in the prior quarter.
  • Across five years, Short term Debt topped out at $19.9 million in Q4 2019 and bottomed at $2.0 million in Q1 2022.
  • The 5-year median for Short term Debt is $5.3 million (2018), against an average of $8.1 million.
  • The largest annual shift saw Short term Debt surged 133.34% in 2021 before it plummeted 82.86% in 2022.
  • A 5-year view of Short term Debt shows it stood at $4.2 million in 2018, then surged by 376.67% to $19.9 million in 2019, then crashed by 74.83% to $5.0 million in 2020, then soared by 133.34% to $11.7 million in 2021, then tumbled by 82.86% to $2.0 million in 2022.
  • Per Business Quant, the three most recent readings for APVO's Short term Debt are $2.0 million (Q4 2022), $2.0 million (Q3 2022), and $2.0 million (Q2 2022).